BACKGROUND: Embryonic stem (ES) cells are distinguished by their capacity for self-renewal and pluripotency. Here we characterize the differentiation of ES cell-derived endothelial cells (ESC-ECs), use molecular imaging techniques to examine their survival in vivo, and determine the therapeutic efficacy of ESC-ECs for restoration of cardiac function after ischemic injury. METHODS AND RESULTS: Murine ES cells were transfected with a construct composed of a vascular endothelial cadherin promoter driving enhanced green fluorescence protein (pVE-cadherin-eGFP). Differentiation of ES cells to ECs was detected by FACS analysis using Flk-1 (early EC marker at day 4) and VE-cadherin (late EC marker at day 8). After isolation, these ESC-ECs express endothelial cell markers similar to adult mouse lung endothelial cells, form vascular-like channels, and incorporate DiI-labeled acetylated low-density lipoprotein (DiI-Ac-LDL). For in vivo imaging, ES cells were transduced with an ubiquitin promoter driving firefly luciferase and monomeric red fluorescence protein (pUb-Fluc-mRFP). A robust correlation exists between Fluc signals and cell numbers by ex vivo imaging analysis (R2=0.98) and by in vitro enzyme assay (R2=0.94). Afterward, 5x10(5) ESC-ECs or PBS (as control) was injected into the hearts of mice undergoing LAD ligation (n=15 per group). Bioluminescence imaging showed longitudinal survival of transplanted ESC-ECs for approximately 8 weeks. Echocardiogram demonstrated significant functional improvement in the ESC-EC group compared with control (P=0.04). Finally, postmortem analysis confirmed increased presence of small capillaries and venules in the infarcted zones by CD31 staining. CONCLUSIONS: This is the first study to track the fate and function of transplanted ESC-ECs in the heart. With further validation, these ESC-ECs could become a valuable source of cell therapy for induction of angiogenesis in the treatment of myocardial ischemia.
BACKGROUND: Embryonic stem (ES) cells are distinguished by their capacity for self-renewal and pluripotency. Here we characterize the differentiation of ES cell-derived endothelial cells (ESC-ECs), use molecular imaging techniques to examine their survival in vivo, and determine the therapeutic efficacy of ESC-ECs for restoration of cardiac function after ischemic injury. METHODS AND RESULTS:Murine ES cells were transfected with a construct composed of a vascular endothelial cadherin promoter driving enhanced green fluorescence protein (pVE-cadherin-eGFP). Differentiation of ES cells to ECs was detected by FACS analysis using Flk-1 (early EC marker at day 4) and VE-cadherin (late EC marker at day 8). After isolation, these ESC-ECs express endothelial cell markers similar to adult mouse lung endothelial cells, form vascular-like channels, and incorporate DiI-labeled acetylated low-density lipoprotein (DiI-Ac-LDL). For in vivo imaging, ES cells were transduced with an ubiquitin promoter driving firefly luciferase and monomeric red fluorescence protein (pUb-Fluc-mRFP). A robust correlation exists between Fluc signals and cell numbers by ex vivo imaging analysis (R2=0.98) and by in vitro enzyme assay (R2=0.94). Afterward, 5x10(5) ESC-ECs or PBS (as control) was injected into the hearts of mice undergoing LAD ligation (n=15 per group). Bioluminescence imaging showed longitudinal survival of transplanted ESC-ECs for approximately 8 weeks. Echocardiogram demonstrated significant functional improvement in the ESC-EC group compared with control (P=0.04). Finally, postmortem analysis confirmed increased presence of small capillaries and venules in the infarcted zones by CD31 staining. CONCLUSIONS: This is the first study to track the fate and function of transplanted ESC-ECs in the heart. With further validation, these ESC-ECs could become a valuable source of cell therapy for induction of angiogenesis in the treatment of myocardial ischemia.
Authors: J Yamashita; H Itoh; M Hirashima; M Ogawa; S Nishikawa; T Yurugi; M Naito; K Nakao; S Nishikawa Journal: Nature Date: 2000-11-02 Impact factor: 49.962
Authors: M Vasa; S Fichtlscherer; A Aicher; K Adler; C Urbich; H Martin; A M Zeiher; S Dimmeler Journal: Circ Res Date: 2001-07-06 Impact factor: 17.367
Authors: Jonathan M Hill; Gloria Zalos; Julian P J Halcox; William H Schenke; Myron A Waclawiw; Arshed A Quyyumi; Toren Finkel Journal: N Engl J Med Date: 2003-02-13 Impact factor: 91.245
Authors: Birgit Assmus; Jörg Honold; Volker Schächinger; Martina B Britten; Ulrich Fischer-Rasokat; Ralf Lehmann; Claudius Teupe; Katrin Pistorius; Hans Martin; Nasreddin D Abolmaali; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher Journal: N Engl J Med Date: 2006-09-21 Impact factor: 91.245
Authors: Shulamit Levenberg; Justin S Golub; Michal Amit; Joseph Itskovitz-Eldor; Robert Langer Journal: Proc Natl Acad Sci U S A Date: 2002-03-26 Impact factor: 11.205
Authors: Volker Schächinger; Birgit Assmus; Martina B Britten; Jörg Honold; Ralf Lehmann; Claudius Teupe; Nasreddin D Abolmaali; Thomas J Vogl; Wolf-Karsten Hofmann; Hans Martin; Stefanie Dimmeler; Andreas M Zeiher Journal: J Am Coll Cardiol Date: 2004-10-19 Impact factor: 24.094
Authors: Dan S Kaufman; Rachel L Lewis; Eric T Hanson; Robert Auerbach; Johanna Plendl; James A Thomson Journal: Blood Date: 2003-10-16 Impact factor: 22.113
Authors: Mingxia Gu; Nicholas M Mordwinkin; Nigel G Kooreman; Jaecheol Lee; Haodi Wu; Shijun Hu; Jared M Churko; Sebastian Diecke; Paul W Burridge; Chunjiang He; Frances E Barron; Sang-Ging Ong; Joseph D Gold; Joseph C Wu Journal: Eur Heart J Date: 2014-11-02 Impact factor: 29.983
Authors: Kitchener D Wilson; Ning Sun; Mei Huang; Wendy Y Zhang; Andrew S Lee; Zongjin Li; Shan X Wang; Joseph C Wu Journal: Cancer Res Date: 2010-06-08 Impact factor: 12.701
Authors: Ping Zhang; Neil Moudgill; Eric Hager; Nicolas Tarola; Christopher Dimatteo; Stephen McIlhenny; Thomas Tulenko; Paul J DiMuzio Journal: Stem Cells Dev Date: 2010-11-01 Impact factor: 3.272